RxDoctor Payments Data

Joseph Hickey, MD

Internal Medicine · Medford, NJNPI 1639197239

Payments from drug & device makers

$5,305in general payments, 2019–2025

Across 383 payments — averaging $13.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$862
  • GSK$762
  • AbbVie$480
  • Amarin Pharma, Inc.$294
  • Lilly USA, LLC$280
  • Amgen$276
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,305 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$121,180
Medicare patients
547
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$138,835
OzempicSemaglutide96$115,149
XareltoRivaroxaban63$67,765
JanuviaSitagliptin Phosphate50$54,996
OxycontinOxycodone Hcl87$46,993
MounjaroTirzepatide40$42,392
JardianceEmpagliflozin25$33,547
FarxigaDapagliflozin Propanediol34$33,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$30,809
TrulicityDulaglutide11$15,723
LinzessLinaclotide13$14,530
Breo ElliptaFluticasone/Vilanterol18$10,952
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,252
TradjentaLinagliptin12$9,484
EntrestoSacubitril/Valsartan13$8,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$138,835134 claims
Novo NordiskOzempic$275$115,14996 claims
Johnson & JohnsonXarelto$112$67,76563 claims
Lilly USA, LLCMounjaro, Trulicity$280$58,11451 claims
MerckJanuvia$133$54,99650 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$762$52,01474 claims
Boehringer IngelheimJardiance, Tradjenta$68$43,03037 claims
AstraZenecaFarxiga, Symbicort$862$41,02148 claims
AbbVieLinzess, Synthroid$480$17,39351 claims
NovartisEntresto$165$8,37613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Medford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →